Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Epitopea Ltd. has signed a license and research collaboration agreement with MSD (Merck & Co. Inc.) to identify Cryptigen tumor-specific antigens in an undisclosed solid tumor. Cryptigen TSAs are ...

Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens through Epitopea’s CryptoMap platform.

Life science company Epitopea, rooted in Cambridge UK and both Montreal and Quebec in Canada, has clinched a licensing deal ...

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, ...

Epitopea has inked a license and research collaboration with Merck to discover new tumor-specific antigens from so-called ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Life science company Epitopea, rooted in Cambridge UK and both Montreal and Quebec in Canada, has clinched a licensing deal and research collaboration with MSD that is potentially worth several ...

Epitopea, an Anglo-Canadian company developing accessible, off-the-shelf RNA-based immunotherapies for cancer, has announced a license and research collaboration deal with US pharma giant Merck & Co ...